LGALS9 and cancer: Ligand LGALS9 with its receptors (CD44, CD47, and HAVCR2) showed that the inflammatory meta program also interacted with immune cells, implying that it is a cysteine/galactose binding protein that can compromise the functions of NK and T cell to facilitate cancer cell immune escape [32].